Abstract: The application discloses an auxiliary method and device for one time programmable (OTP) adjustment of a display panel. The auxiliary method includes: crimping and conducting a flexible circuit board to a display panel bonded with a chip by means of pre-bonding, to lead a crimping impedance by the flexible circuit board; detecting the crimping impedance led by the flexible circuit board; and screening a detected crimping impedance value to determine whether the OTP adjustment is enabled, wherein when the crimping impedance value meets a preset condition, the OTP adjustment is enabled, and when the crimping impedance value does not meet the preset condition, the OTP adjustment is disabled.

Abstract: The application discloses an auxiliary method and device for one time programmable (OTP) adjustment of a display panel. The auxiliary method includes: crimping and conducting a flexible circuit board to a display panel bonded with a chip by means of pre-bonding, to lead a crimping impedance by the flexible circuit board; detecting the crimping impedance led by the flexible circuit board; and screening a detected crimping impedance value to determine whether the OTP adjustment is enabled, wherein when the crimping impedance value meets a preset condition, the OTP adjustment is enabled, and when the crimping impedance value does not meet the preset condition, the OTP adjustment is disabled.

Abstract: The present invention discloses a water-soluble docetaxel anticancer drug compound having the structure of Formula I below: in which R=—CH3, —CH2CH3, —CH2CH2CH3, or —CH2CH2CH2CH3; and n=5-500. The active moiety docetaxel in the anticancer drug compound is covalently conjugated to a polyethylene glycol monoalkyl ether through a linker diglycoloyl (carbonyl methoxyacetyl) to form the water-soluble docetaxel anticancer drug compound. The present invention also relates to a preparation method of the drug compound and use thereof.

Abstract: The present invention discloses a water-soluble docetaxel anticancer drug compound having the structure of Formula I below: in which R=—CH3, —CH2CH3, —CH2CH2CH3, or —CH2CH2CH2CH3; and n=5-500. The active moiety docetaxel in the anticancer drug compound is covalently conjugated to a polyethylene glycol monoalkyl ether through a linker diglycoloyl (carbonyl methoxyacetyl) to form the water-soluble docetaxel anticancer drug compound. The present invention also relates to a preparation method of the drug compound and use thereof.

Abstract: The present disclosure provides an information processing method and an electronic device. The method comprises: detecting and obtaining first information, the first information being information communicated by a first user using a first electronic device with another user; determining whether there is a first file associated with the first information and satisfying a predetermined condition based on the first information; and storing, when it is determined that there is a first file associated with the first information and satisfying the predetermined condition, the first file in a network storage space associated with the first user, the network storage space being different from a first storage space where the first information is stored.

Abstract: Disclosed is a trolox derivative-modified fat-soluble anti-cancer pharmaceutical compound having a structure as represented by formula I or II. An active moiety of the anti-cancer pharmaceutical compound, camptothecin or a camptothecin derivative, is covalently bonded to a lipophilic moiety, a trolox ester or a trolox amide, by a linking group to form the fat-soluble anti-cancer pharmaceutical compound. Also disclosed are a preparation, preparing method and use of the pharmaceutical compound.

Abstract: Disclosed is a trolox derivative-modified fat-soluble anti-cancer pharmaceutical compound having a structure as represented by formula I or II. An active moiety of the anti-cancer pharmaceutical compound, camptothecin or a camptothecin derivative, is covalently bonded to a lipophilic moiety, a trolox ester or a trolox amide, by a linking group to form the fat-soluble anti-cancer pharmaceutical compound. Also disclosed are a preparation, preparing method and use of the pharmaceutical compound.

Abstract: The present invention relates to novel methods of synthesis of therapeutic and diagnostic dendrimers. In particular, the present invention is directed to novel dendrimer conjugates, novel methods of synthesizing the same, compositions comprising the conjugates, as well as systems and methods utilizing the conjugates (e.g., in diagnostic and/or therapeutic settings (e.g., for the delivery of therapeutics, imaging, and/or targeting agents (e.g., in disease (e.g., cancer, inflammatory disease) diagnosis and/or therapy, pain therapy, etc.)). Accordingly, dendrimer conjugates of the present invention may further comprise at least two different components for targeting, imaging, sensing, and/or providing a therapeutic or diagnostic material and/or monitoring response to therapy. Furthermore, the novel synthesis methods of certain embodiments of the present invention provide significant advantages with regard to total reaction time and simplicity.

Abstract: Lipophilic anticancer drug compounds, compositions that include the compounds, and methods for treating a cell proliferative disease using the compounds.

Abstract: Lipophilic di(anticancer drug) compounds, compositions that include the compounds, and methods for treating a cell proliferative disease using the compounds.

Abstract: Tocopherol-modified therapeutic drug compounds; emulsion, microemulsion, and micelle formulations that include the compounds; methods for making the compounds and formulations; methods for administering the compounds and formulations; and methods for treating conditions using the compounds and formulations.

Abstract: Tocopherol-modified therapeutic drug compounds; emulsion, microemulsion, and micelle formulations that include the compounds; methods for making the compounds and formulations; methods for administering the compounds and formulations; and methods for treating conditions using the compounds and formulations.

Abstract: Lipophilic di(anticancer drug) compounds, compositions that include the compounds, and methods for treating a cell proliferative disease using the compounds.

Abstract: Lipophilic anticancer drug compounds, compositions that include the compounds, and methods for treating a cell proliferative disease using the compounds.

Abstract: Tocopherol-modified therapeutic drug compounds; emulsion, microemulsion, and micelle formulations that include the compounds; methods for making the compounds and formulations; methods for administering the compounds and formulations; and methods for treating conditions using the compounds and formulations.

Abstract: Fluorinated compounds and emulsions including the compounds. The compositions are useful as oxygen carriers and surfactants. In one embodiment, the fluorinated compound is pH sensitive. In one embodiment, the fluorinated compound is a vitamin E derivative. In one embodiment, the fluorinated compound is a vitamin K derivative.

Abstract: Tocopherol-modified therapeutic drug compounds; emulsion, microemulsion, and micelle formulations that include the compounds; methods for making the compounds and formulations; methods for administering the compounds and formulations; and methods for treating conditions using the compounds and formulations.

Abstract: A nanoporous reactive adsorbent incorporates a relatively small number of relatively larger reactant, e.g., metal, enzyme, etc., particles (10) forming a discontinuous or continuous phase interspersed among and surrounded by a continuous phase of smaller adsorbent particles (12) and connected interstitial pores (14) therebetween. The reactive adsorbent can effectively remove inorganic or organic impurities in a liquid by causing the liquid to flow through the adsorbent. For example, silver ions may be adsorbed by the adsorbent particles (12) and reduced to metallic silver by reducing metal, such as irons, as the reactant particles (10). The column can be regenerated by backwashing with the liquid effluent containing, for example, acetic acid.

Abstract: The present invention relates to a method of detecting the CACNA1H mutant gene of childhood absence epilepsy-the main function gene, the said method is directly sequencing or restriction analysis. The present invention relates to CACNA1H mutant gene. The present invention further relates to the use of the said detection and mutant gene. The present invention connects the CACNA1H gene with medicine for treating childhood absence epilepsy, proving new target site for medicine for treating the same. The present invention establishes the foundation for developing new medicines for treating childhood absence epilepsy and other type of idiopathic system epilepsy as well as other system diseases associated with CACNA1H gene.

Abstract: Fluorinated compounds and emulsions including the compounds. The compositions are useful as oxygen carriers and surfactants. In one embodiment, the fluorinated compound is pH sensitive. In one embodiment, the fluorinated compound is a vitamin E derivative. In one embodiment, the fluorinated compound is a vitamin K derivative.